Litigation Details for In Re: Aggrenox Antitrust Litigation (D. Conn. 2014)
✉ Email this page to a colleague
In Re: Aggrenox Antitrust Litigation (D. Conn. 2014)
| Docket | ⤷ Try a Trial | Date Filed | 2014-04-03 |
| Court | District Court, D. Connecticut | Date Terminated | 2018-07-19 |
| Cause | MDL 2516 In Re: Aggrenox Antitrust Litigation | Assigned To | Stefan R. Underhill |
| Jury Demand | None | Referred To | |
| Patents | 10,011,659; 6,015,577; 9,029,146 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in In Re: Aggrenox Antitrust Litigation
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Biologic Drugs cited in In Re: Aggrenox Antitrust Litigation
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for In Re: Aggrenox Antitrust Litigation (D. Conn. 2014)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2014-06-17 | 101 | Amended Complaint | Boehringer’s U.S. Patent No. 6,015,577 (the “’577 Patent”)—even though the ’577 Patent was likely invalid…Aggrenox NDA, Boehringer submitted Patent No. 6,015,577 (the ‘577 Patent) to the FDA for listing in the … ‘577 Patent, asserting that its generic would not infringe the patent and/or that the patents was invalid…at-risk” (i.e., while the patent litigation was pending); (b) upon winning the patent litigation; or (c) pursuant…brand name drug’s patents listed in the Orange Book, because either: (a) no patents exist on the brand | External link to document |
| 2014-08-22 | 182 | Memorandum in Opposition to Motion | eliminate the risk that Boerhinger’s U.S. Patent No. 6,015,577 would be invalidated, Defendants entered…at all, asserting that the patent was invalid and not infringed: “The patent here may or may not be valid…........................... 15 In re Buspirone Patent Litig., 185 F. Supp. 2d 363 (S.D.N.Y. 2002…inter-generic competition for the duration of the patent term. Id. ¶¶ 94-95. Under the Agreement, there …between possible generic entry and the end of the patent term. Id. For all the reasons discussed | External link to document |
| 2015-03-23 | 229 | Order on Motion to Dismiss | Boehringer obtained U.S. Patent No. 6,015,577 on the composition (“the ’577 patent”), after having obtained… no such patent has been filed, that such patent has expired, the date on which such patent will expire…of the patent, in exchange for the defendant dropping its patent challenge. Assuming the patent is valid…incentives to undertake patent litigation under the Drug Price Competition and Patent Term Restoration Act…procedures relating to patent disputes and contains provisions that encourage patent challenges. A drug | External link to document |
| 2015-05-15 | 263 | Amended Complaint | Boehringer’s U.S. Patent No. 6,015,577 (the “’577 Patent”)—even though the ’577 Patent was likely invalid…Aggrenox NDA, Boehringer submitted Patent No. 6,015,577 (the ‘577 Patent) to the FDA for listing in the … ‘577 Patent, asserting that its generic would not infringe the patent and/or that the patents was invalid…at-risk” (i.e., while the patent litigation was pending); (b) upon winning the patent litigation; or (c) pursuant…brand name drug’s patents listed in the Orange Book, because either: (a) no patents exist on the brand | External link to document |
| 2014-05-12 | 47 | Memorandum in Support of Motion | infringed Boehringer's U.S. Patent No. 6,015,577 (the "'577 Patent"), which expires in January…FDA that its generic did not infringe any valid patent held by Boehringer that covered Aggrenox. Shortly… (a) discontinue its challenge to the '577 Patent and (b) delay selling a generic version of Aggrenox…reverse payments that Boehringer gave to its alleged patent infringer Barr. In or around early 2009 | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
